Current Drug Therapies for Rosacea: A Chronic Vascular and Inflammatory Skin Disease

Feldman, Steven R.; Huang, William W.; Huynh, Tu T.

doi:10.18553/jmcp.2014.20.6.623

Cited by 14 publications

(16 citation statements)

References 59 publications

(67 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Erythema of rosacea is an extremely complex condition involving both vascular and inflammatory events . Several treatments exist to treat the inflammatory component of rosacea but there are few effective treatments directly targeting the erythema .…”

Section: Introductionmentioning

confidence: 99%

“…7,8 Erythema of rosacea is an extremely complex condition involving both vascular and inflammatory events. 1,9 Several treatments exist to treat the inflammatory component of rosacea but there are few effective treatments directly targeting the erythema. 10,11 The only approved topical treatment for facial erythema of rosacea is brimonidine gel 0.33% (Mirvaso â ; Galderma SA, Lausane, Switzerland) (1 g of gel contains 3.3 mg of brimonidine, equivalent to 5 mg of brimonidine tartrate), which received FDA approval in August 2013 and centralized EMA approval in December 2013.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Brimonidine gel 0.33% rapidly improves patient‐reported outcomes by controlling facial erythema of rosacea: a randomized, double‐blind, vehicle‐controlled study

Layton

Schaller

Homey

et al. 2015

Acad Dermatol Venereol

View full text Add to dashboard Cite

BackgroundFacial redness contributes to impaired psychosocial functioning in rosacea patients and the only approved treatment for erythema is topical brimonidine gel 0.33%.ObjectivesTo evaluate patient‐reported outcomes, as well as efficacy and safety, in subjects with self‐perceived severe erythema treated with brimonidine gel 0.33% compared to vehicle.MethodsAn 8‐day multicenter, randomized study comparing once‐daily brimonidine gel 0.33% with vehicle gel using a facial redness questionnaire, subject satisfaction questionnaire and a patient diary of facial redness control to assess patient‐reported outcomes.ResultsOf the 92 included subjects with self‐perceived severe erythema, very few were satisfied with their appearance at baseline (4.2% brimonidine group, 0 vehicle group). On Day 8, significantly more brimonidine group subjects were satisfied with their facial appearance compared to vehicle group (36.9% vs. 21.5%; P < 0.05), with the overall treatment effect (69.6% vs. 40.4%; P < 0.01), and with the improvement in their facial redness (67.4% vs. 33.3%; P < 0.001). More brimonidine group subjects were able to control their facial redness daily (e.g. 83.0% vs. 38.9% on Day 1). On Day 8, significantly more brimonidine group subjects than vehicle group had at least a one‐grade improvement from baseline in the Clinician Erythema Assessment score (71.7% vs. 35.7%; P = 0.0011) and Patient Self‐Assessment score (76.1% vs. 47.6%; P = 0.004). More subjects in the brimonidine group (29.2%) reported treatment‐related adverse events than in the vehicle group (15.9%) but most were mild and transient.ConclusionsOnce‐daily brimonidine gel 0.33% allowed patients to rapidly control their facial redness and significantly improved patient‐reported outcomes in the treatment of persistent facial erythema of rosacea.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Brimonidine gel 0.33% rapidly improves patient‐reported outcomes by controlling facial erythema of rosacea: a randomized, double‐blind, vehicle‐controlled study

Layton

Schaller

Homey

et al. 2015

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…Rosacea is a chronic inflammatory dermatosis with an unpredictable course and the characteristic features of persistent erythema associated with periodic intensification or 'flares' (1)(2)(3). Due to the visibility of rosacea features, subjects are often exposed to social stigmatization, which adds considerable psychosocial burden to the subject's psychological and emotional health (4-7).…”

Section: Introductionmentioning

confidence: 99%

Characterizing high-burden rosacea subjects: a multivariate risk factor analysis from a global survey

Tan

Steinhoff

Bewley

et al. 2019

Journal of Dermatological Treatment

View full text Add to dashboard Cite

Objective: To characterize rosacea features suitable for identification of high-burden (HB) subjects in clinical practice. Design: Global online survey with subjects recruited using an online panel from the United States, Canada, Italy, United Kingdom, Germany and France. Subjects self-reported a physician's diagnosis of rosacea. Measurements: HB subjects were defined as those with !3/4 domains (quality of life, lifestyle adaptation, time trade-off, willingness to pay) greater than the median. Group characteristics were analyzed and multivariate-logistic modeling used to investigate factors most associated with HB. Results: 710 subjects completed the survey, including 158 HB subjects. HB was observed in all selfdeclared rosacea severities. HB subjects were more likely to spend more time daily on skin care and experienced approximately double the impact of health problems on work productivity in the past 7 days (p < .01). In the past 12 months, HB subjects were more likely to have at least one visit to the emergency room (41.8% vs 11.2%; p < .01). In the multivariate risk analysis, factors most associated with HB included rosacea severity, impact of health problems on regular daily activities and age at first symptoms. Conclusion: Rosacea has a distinct subset of HB subjects who can be successfully characterized.

show abstract

“…Several therapeutic approaches are currently available for treating rosacea and they are mainly aimed at controlling disease symptoms [40,41]. The therapeutic plan has to be adapted to the rosacea subtype and tailored according to the dominant manifestations of the patient [32,35].…”

Section: Discussionmentioning

confidence: 99%

Coupled blue and red light-emitting diodes therapy efficacy in patients with rosacea: two case reports

Sorbellini¹,

Padova

Rinaldi³

2020

J Med Case Reports

View full text Add to dashboard Cite

Background: Rosacea is a common inflammatory skin condition affecting approximately 5% of the world population. Therapeutic approaches to rosacea are focused on symptom suppression by means of antiinflammatory agents. More recently, photodynamic therapy, especially light-emitting diodes, has been introduced as a valid alternative to conventional therapy. Case presentation: In the present work, we reported the efficacy and safety of light-emitting diodes therapy combining blue (480 nm) and red (650 nm) light for the treatment of two patients with papulopustular rosacea: a 22-year-old Caucasian woman and a 68-year-old Caucasian man. Conclusions: This kind of treatment could represent an effective, safer, and well-tolerated approach for the treatment of such conditions.

show abstract

Current Drug Therapies for Rosacea: A Chronic Vascular and Inflammatory Skin Disease

Abstract: BACKGROUND: Rosacea is a chronic skin disorder that presents with abnormal vascular and inflammatory conditions. Clinical manifestations include flushing, facial erythema, inflammatory papules and pustules, telangiectasias, edema, and watery or irritated eyes.

Cited by 14 publications

References 59 publications

Brimonidine gel 0.33% rapidly improves patient‐reported outcomes by controlling facial erythema of rosacea: a randomized, double‐blind, vehicle‐controlled study

Brimonidine gel 0.33% rapidly improves patient‐reported outcomes by controlling facial erythema of rosacea: a randomized, double‐blind, vehicle‐controlled study

Characterizing high-burden rosacea subjects: a multivariate risk factor analysis from a global survey

Coupled blue and red light-emitting diodes therapy efficacy in patients with rosacea: two case reports

Contact Info

Product

Resources

About